Drug Profile

SB 509

Alternative Names: hVEGF-A; SB-509; VEGF activator zinc finger protein

Latest Information Update: 12 Jan 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sangamo BioSciences
Class Gene therapies; Neuroprotectants; Zinc finger DNA binding proteins
Mechanism of Action Gene transference; Genetic transcription stimulants; Vascular endothelial growth factor A expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Amyotrophic lateral sclerosis; Brain injuries; Diabetic neuropathies; Spinal cord injuries; Stroke

Most Recent Events

06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
03 Oct 2011 Discontinued - Phase-II for Amyotrophic lateral sclerosis in USA (IM)
03 Oct 2011 Discontinued - Phase-II for Diabetic neuropathies in USA (IM)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com